Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Neuphoria Therapeutics (NEUP) over the last 6 years, with Q4 2025 value amounting to $22.2 million.

  • Neuphoria Therapeutics' Cash & Equivalents rose 41030.07% to $22.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $22.2 million, marking a year-over-year increase of 41030.07%. This contributed to the annual value of $14.2 million for FY2025, which is N/A changed from last year.
  • As of Q4 2025, Neuphoria Therapeutics' Cash & Equivalents stood at $22.2 million, which was up 41030.07% from $13.6 million recorded in Q3 2025.
  • Over the past 5 years, Neuphoria Therapeutics' Cash & Equivalents peaked at $29.4 million during Q4 2021, and registered a low of $4.3 million during Q4 2024.
  • Over the past 5 years, Neuphoria Therapeutics' median Cash & Equivalents value was $14.2 million (recorded in 2025), while the average stood at $16.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 4926.37% in 2023, then soared by 41030.07% in 2025.
  • Quarter analysis of 5 years shows Neuphoria Therapeutics' Cash & Equivalents stood at $29.4 million in 2021, then decreased by 18.22% to $24.0 million in 2022, then plummeted by 49.26% to $12.2 million in 2023, then plummeted by 64.38% to $4.3 million in 2024, then surged by 410.3% to $22.2 million in 2025.
  • Its Cash & Equivalents stands at $22.2 million for Q4 2025, versus $13.6 million for Q3 2025 and $14.2 million for Q2 2025.